Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 58fludarabine phosphate 53Mycophenolic Acid 36Whole-Body Irradiation 35Peripheral Blood Stem Cell Transplantation 35Busulfan 33Cyclosporine 32Antilymphocyte Serum 27Tacrolimus 26Melphalan 25Filgrastim 22Cord Blood Stem Cell Transplantation 21fludarabine 20Radiotherapy 20Methotrexate 16Methylprednisolone 15Thiotepa 12Etoposide 11Cytarabine 11Granulocyte Colony-Stimulating Factor 7Cyclosporins 7Rituximab 6thymoglobulin 5Sirolimus 5Leucovorin 4Bortezomib 4Bone Marrow Transplantation 4sargramostim 3merphos 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Brentuximab Vedotin × Classical hematology × Clear all
NCT01461538 2016-03-04

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Seagen Inc.

Phase 2 Completed
84 enrolled 20 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡